不可切除肝细胞癌阿替利珠单抗联合贝伐珠单抗长期生存的决定因素
AB-Real多中心注册研究分析1085例不可切除肝细胞癌一线阿替利珠单抗联合贝伐珠单抗治疗患者,中位OS 19.2个月,2年和3年生存率分别为41.4%和29.3%。影像学缓解者长期生存显著优于无缓解者(52.2% vs 8.8%),长期生存与基线肿瘤负荷及肝功能密切相关。
要点
- 影像学缓解者24个月长期生存率显著更高(52.2% vs 8.8%)。
- ALBI 1级、无门静脉侵犯、肿瘤小及AFP低与长期生存相关。
- 近半数影像学缓解者未达长期生存,基线不良特征仍影响预后。
核心结论
- AB-Real提供首个全球真实世界证据,显示阿替利珠单抗联合贝伐珠单抗在uHCC中影像学缓解者长期生存显著改善,且与治疗前肿瘤因素和肝功能强相关。
研究设计与样本
- AB-Real为跨越欧洲、亚洲和美国的-large多中心注册研究,分析1346例中1085例Child-Pugh A且ECOG 0-1接受一线A+B治疗的患者。
主要发现
- 中位OS为19.2个月(95%CI: 17.6-20.9),2年和3年生存率分别为41.4%和29.3%。
- 695例随访充分患者中190例为长期生存者,总体缓解率24.7%。
- 影像学缓解者长期生存率52.2%,无缓解者8.8%(p < 0.001)。
- 长期生存者较非长期生存者更常见ALBI 1级(64.6% vs 38.5%)、较少门静脉侵犯(17.9% vs 36.4%)、最大肿瘤更小(3.8 vs 7.0 cm)、AFP更低(中位23.0 vs 240.8 ng/mL)(均p < 0.001)。
- 48.8%的影像学缓解但未达长期生存者具有≥2项基线不良特征。
临床怎么用
- 对于uHCC一线A+B治疗,应评估基线肿瘤负荷和肝功能以预判长期生存可能。
- 影像学缓解者仍需关注基线不良特征,因近半数缓解者未达长期生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the proven superiority against sorafenib, atezolizumab plus bevacizumab (A+B) lacks long-term efficacy data in unresectable hepatocellular carcinoma (uHCC). This study assessed clinicopathologic factors associated with long-term survival with A+B. METHODS: We analyzed patients receiving first-line A+B within AB-Real, a large multicenter registry across Europe, Asia, and the USA. Long-term survivors (LTS) were defined as patients surviving at 24 months. Landmark survival outcomes and associations between baseline clinicopathologic factors and overall survival (OS) were evaluated. RESULTS: Of 1346 patients enrolled, 1085 with Child-Pugh A and ECOG 0-1 received first-line A+B. The median OS was 19.2 months (95% CI: 17.6-20.9), and 2- and 3-year survival rates were 41.4% and 29.3%. Among 695 patients with adequate follow-up, 190 were classified as LTS. The overall response rate was 24.7%, and long-term survivorship was significantly enhanced in radiologic responders (52.2% vs 8.8%, p < 0.001). Compared to non-LTS, LTS more frequently had ALBI grade 1 liver reserve (64.6% vs 38.5%), less PVI (17.9% vs 36.4%), smaller maximum tumor size (3.8 vs 7.0 cm), and lower AFP (median 23.0 vs 240.8 ng/mL) (all p < 0.001). Notably, nearly half (48.8%) of radiologic responders who did not achieve long-term survival had ≥ 2 adverse baseline features, underscoring that tumor burden and liver reserve remain prognostically relevant even among responders. CONCLUSIONS: AB-Real provides the first global real-world evidence of long-term efficacy of A+B in uHCC. Long-term survivorship is enhanced in radiological responders and strongly associated with pre-treatment tumor factors and liver function.
引用
- Lee PC, Cortellini A, Stefanini B, et al. Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. Eur J Cancer. 2026. PMID: 42030777. doi:10.1016/j.ejca.2026.116749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。